EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Evaxion A/S
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$3.33+0.50 (+17.67%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.46 (−50.96%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Evaxion A/S grew revenue 125.1% to $7.53M over fiscal 2025. Free cash flow was -$6.64M.
Revenue
$7.53M
+125.1% vs. a year earlier
Operating income
-$9.23M
FY2025
Free cash flow
-$6.64M
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $7.53M
- Net income
- -$7.71M
- Free cash flow
- -$6.64M
Nine years at a glance
Fiscal years 2017 to 2025, USD
Revenue
$7.53M+125.1% YoY
Operating income
-$9.23M
Net income
-$7.71M
EPS, diluted
–
Free cash flow
-$6.64M
Reported period